Adalimumab
What is it: A lab-engineered antibody that precisely dampens immune-driven inflammation.AKA: ABP 501, Abrilada, Amjevita, Exemptia, Hulio, Humira, Hyrimoz, Idacio- ⬤ Minimal research: Very little scientific study exists, with no or very few peer-reviewed studies. Insufficient data for conclusions.
- ⬤⬤ Limited research: Few studies exist, mostly small trials or case reports. Findings are preliminary and lack strong validation.
- ⬤⬤⬤ Moderately researched: Multiple studies, including mid-sized trials, exist. Some findings are replicated, but more research is needed.
- ⬤⬤⬤⬤ Well-researched: Supported by substantial evidence, including at least one large trial or meta-analysis.
- ⬤⬤⬤⬤⬤ Extensively studied: Numerous large studies and meta-analyses exist. Findings are widely accepted with strong scientific consensus.
- ⬤ Extremely Difficult to Access: Rare, experimental, or highly specialized. Requires multiple referrals, long wait times, travel, and strict follow-up.
- ⬤⬤ Difficult to Access: Limited to select centers with moderate barriers. Requires referral, potential travel, and wait times of weeks to months.
- ⬤⬤⬤ Moderately Accessible: Available in larger hospitals or clinics. Requires a basic referral, with moderate wait times and some coordination.
- ⬤⬤⬤⬤ Easy to Access: Widely available in most clinics. Minimal referral, short wait times, and simple preparation or follow-up.
- ⬤⬤⬤⬤⬤ Trivial to Access: Easily found in pharmacies or clinics. No referral needed, minimal wait, and straightforward access.
- ⬤ Up to $100
- ⬤⬤ Up to $500
- ⬤⬤⬤ Up to $2000
- ⬤⬤⬤⬤ Up to $10,000
- ⬤⬤⬤⬤⬤ More than $10,000
To calculate the reported effectiveness for a patient view, the model first analyses whether it can be ascertained that the person writing the review has had direct experience of the treatment for themselves or a loved one. If so, it then uses sentiment analysis to rate their view from 1-5 on how effective this treatment was for them, with 1 being the least effective, and 5 the most effective.
5 Patient views
Contributed in this guide
Figure out what Adalimumab means for you
Page contents
Basics: What you need to know
Adalimumab is a carefully engineered monoclonal antibody that hinders TNF-α activity, which helps control severe inflammation. Commonly known by brand names such as Humira, Amjevita, and others, it has shown benefits in chronic autoimmune conditions like rheumatoid arthritis and Crohn’s disease. In the context of prolonged post-viral syndromes, there is growing interest in exploring whether its immunomodulatory effects might help some individuals seeking relief from pronounced inflammatory symptoms. Nonetheless, its suitability and effectiveness for such uses remain under investigation, requiring careful monitoring.
History and development
- Early research: Created through a collaboration involving Cambridge Antibody Technology, this monoclonal antibody was first identified with the code D2E7, then licensed for large-scale production.
- AbbVie’s role: AbbVie (previously part of Abbott) further refined and commercialized it, becoming the first fully human monoclonal antibody to gain regulatory approvals.
- Regulatory milestones: After initial U.S. FDA approval in 2002, multiple indications followed, expanding its target usage in varied inflammatory conditions.
- Biosimilar expansions: Manufacturers worldwide developed near-identical versions (biosimilars), meeting rigorous testing requirements for efficacy and safety.
What is known
- TNF-α neutralization: By blocking TNF-α, it reduces inflammation—a mechanism relevant in disorders marked by immune system overactivity.
- Inflammation reduction: Its primary role centers on curbing inflammatory cascades that can damage tissues and organs when uncontrolled.
- Potential for respiratory support: In select post-viral conditions, controlling systemic inflammation may help alleviate persistent lung inflammation, though definitive proof remains limited.
- Lesser-known benefits: Some patients report reduced fatigue, skin advantages (e.g., improvement in psoriasis-like features), and a possible decrease in specific inflammatory markers.
What is not known
- Long-term outcomes: Effects on prolonged post-viral states require more research to confirm safety and sustained symptom relief.
- Optimal dosing: Precise protocols specific to new or off-label uses are unclear, and the best dosage or frequency remains to be thoroughly established.
- Individual variation: Differences in immune profiles mean that some people with persistent inflammation may respond well, while others see minimal effect.
- Rare complications: The likelihood of unusual adverse events, such as reactivation of latent viruses, is yet to be fully clarified in newer applications.
- Biologic design: It is produced through recombinant DNA technology to target TNF-α.
- TNF-α blockade: By attaching to TNF-α, it prevents harmful inflammatory signaling.
- Immune balance: Suppressing excessive immune activity can reduce joint, gut, and organ inflammation.
- Regulated pathway: It undergoes strict manufacturing processes to maintain consistency and purity.
- Serious infections: Immune suppression can raise the risk of bacterial and viral infections.
- Injection site reactions: Some individuals experience redness, swelling, or itching.
- Allergic responses: Rarely, rashes or hypersensitivity can occur.
- Potential malignancy risk: Prolonged TNF-α inhibition might slightly increase certain cancer risks.
- Off-label debates: Experts differ on extending use beyond approved indications.
- Cost concerns: The price of complex biologics can limit broader adoption.
- Long COVID exploration: While some clinicians see promise, large-scale data remain scarce.
- Insurance coverage: Access might be challenging if usage is experimental or off-label.
Patient views
Experiences
- Patients appreciate its ability to reduce inflammation and symptoms like brain fog.
- Some report significant relief from heart-related symptoms and palpitations.
- It has helped improve cognitive function and reduce neuroinflammation.
- Easy self-injection process is preferred over other delivery methods.
Challenges
- Concerns about lack of placebo-controlled trials for long Covid.
- Risk of adverse reactions, especially in ME/CFS patients.
- Uncertainty about long-term effects and safety.
- Some find injections painful if administered incorrectly.
Tips
- Ensure proper injection technique to avoid pain.
- Monitor inflammatory markers and cytokines regularly.
- Consult specialists familiar with immune-modulating treatments.
- Consider combining with other therapies for better outcomes.
To calculate the reported effectiveness for a patient view, the model first analyses whether it can be ascertained that the person writing the review has had direct experience of the treatment for themselves or a loved one. If so, it then uses sentiment analysis to rate their view from 1-5 on how effective this treatment was for them, with 1 being the least effective, and 5 the most effective.
Patient view
I take adalimumab for ankylosing spondylitis and have for years before covid. My questions are for others who take a similar drug:
• at least in my country blood tests are taken every 3 months to monitor the drug. If you’ve had yours taken - Have you noticed differences in blood cell counts since covid or in other parameters?
• if you take other medication (such as LDN, betablockers etc.) - Have you noticed side effects or cross effects between all these meds?
• Have you in general heard about how either the biological drug or the underlying disease might affect long covid?
• do you want to share something else regarding this topic?
Neither my rheumatologist or neurologist seen to be very informed about these things, so i’m reaching out to hear about others’ experiences.
Tldr: Has the use of a biological drug to an autoimmune disease affected your long covid treatment or progression somehow?
September 2024 • /r/LongCovid
Patient view
I took Humira injections for years. Same delivery system and it sucks for like a second and then you’re totally fine. Rarely, I’d inject at the wrong spot and hit some muscle and not just fat and it stung a bit more but never any lingering pain or enough to keep me home or anything. Also I injected my inner thigh, fleshiest part I could find. My at home injections of Humira were better than getting vaxxed in the shoulders at the pharmacy and doing years of allergy shots in the shoulders at my doctor’s office. I’d do five injections a day to get rid of my LC or lessen my symptoms haha
October 2024 • /r/covidlonghaulers
What and who it targets
Autoimmune-like symptom patients
Immune dysregulation linked to Long Covid.
Joint pain patients
Severe joint pain linked to inflammation.
Fatigue with inflammatory markers
Fatigue linked to elevated inflammatory markers.
Chronic inflammation sufferers
Persistent inflammation unresponsive to other treatments.
Accessibility
- ⬤ Extremely Difficult to Access: Rare, experimental, or highly specialized. Requires multiple referrals, long wait times, travel, and strict follow-up.
- ⬤⬤ Difficult to Access: Limited to select centers with moderate barriers. Requires referral, potential travel, and wait times of weeks to months.
- ⬤⬤⬤ Moderately Accessible: Available in larger hospitals or clinics. Requires a basic referral, with moderate wait times and some coordination.
- ⬤⬤⬤⬤ Easy to Access: Widely available in most clinics. Minimal referral, short wait times, and simple preparation or follow-up.
- ⬤⬤⬤⬤⬤ Trivial to Access: Easily found in pharmacies or clinics. No referral needed, minimal wait, and straightforward access.
- ⬤ Up to $100
- ⬤⬤ Up to $500
- ⬤⬤⬤ Up to $2000
- ⬤⬤⬤⬤ Up to $10,000
- ⬤⬤⬤⬤⬤ More than $10,000
Method to access
- Requires a prescription from a specialist.
- Typically administered in a clinical setting.
- Biosimilars may be available at lower costs.
- Not commonly prescribed for Long Covid; consult specialized clinics.
Cost
- In the UK, costs range from £357.50 per syringe to £9,295 annually.
- In the US, biosimilars cost $551–$3,924 for two kits, while Humira averages $7,300 for two pens.
- In India, Cipla Adalimumab costs ₹7,000 per box.
Insurance cover
- Commonly covered for approved conditions like rheumatoid arthritis and Crohn's disease.
- Coverage for Long Covid is unclear and may require prior authorization.
- In the US, Medicare and Medicaid may cover biosimilars; commercial insurance often requires copay cards.
Locations
- Cleveland Clinic offers Long Covid treatment and research opportunities.
- Humira biosimilars are available globally, including in the US, UK, and India.
- Specialized clinics for autoimmune conditions may provide access.
Frequently asked questions
Explore other treatments
It's a lot of information, isn't it?
Turnto's personal AI Assistant can help you figure out what this all means for you
© 2026 Turnto
